Increased Incidence of Malignancy During Chronic Renal Failure

Matas, A. J.; Kjellstrand, C.M.; Simmons, R. L.; Buselmeier, T. J.; Najarian, J. S.

doi:10.1016/s0140-6736(75)91684-0

Cited by 325 publications

(146 citation statements)

References 13 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…1,2 In a recent study, Cengiz reported that 188 organ tumors (6.7%) of various pathologies were identified in 2817 patients who had chronic renal failure. 3 Although it is known as a common pathology in the general population, 4 currently, the incidence of renal insufficiency (RI) among patients with cancer remains unclear.…”

Section: Resultsmentioning

confidence: 99%

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

Launay‐Vacher

Oudard

Janus

et al. 2007

Cancer

409

212

View full text Add to dashboard Cite

BACKGROUND. The Renal Insufficiency and Cancer Medications (IRMA) study is a French national observational study. The results from this study of nearly 5000 patients demonstrated the high prevalence of renal impairment in a population of patients with solid tumors. METHODS. Every cancer patient who presented at oncology departments that participated in the study over at least 1 of 2 predefined periods during 2004 were included. Renal function was calculated using Cockcroft‐Gault and abbreviated Modification of Diet in Renal Disease (aMDRD) formulae to estimate the prevalence of renal insufficiency (RI) according to the Kidney Disease Outcomes Quality Initiative‐Kidney Disease Improving Global Outcomes definition and stratification. Anticancer drugs were studied with regard to their potential renal toxicity and dosage adjustment. RESULTS. Of the 4684 patients from the 15 centers, 7.2% had serum creatinine levels >110 μmol/L. However, when they were assessed using Cockcroft‐Gault and aMDRD formulae, 57.4% and 52.9% of patients had abnormal renal function or RI, respectively. Of the 7181 anticancer drug prescriptions, 53.4% required dose adjustments for RI. Of the patients treated, 79.9% received at least 1 such drug. And 80.1% received potentially nephrotoxic drugs. CONCLUSIONS. RI was common in patients with cancer, and drug dosage adjustments often were necessary. Renal function should be evaluated in all cancer patients using either the Cockcroft‐Gault formula or the aMDRD formula, including patients with normal serum creatinine levels. In patients who are at high risk for drug toxicity, the dosage should be adapted to renal function, and the use of nephrotoxic therapies should be avoided whenever possible. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

Launay‐Vacher

Oudard

Janus

et al. 2007

Cancer

409

212

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown an increased overall risk of cancer in persons with ESRD requiring RRT, [4][5][6][7][8][9][10][11] but the impact of less severe kidney dysfunction and cancer risk has been less certain. [12][13][14][15] In contrast to our findings, two prior studies found an association between renal function and overall cancer risk, 13,14 whereas another study found no association between CKD and cancer risk in diabetic patients.…”

Section: Discussionmentioning

confidence: 99%

“…Although multiple studies have observed higher risks of cancer in persons with ESRD requiring dialysis or renal transplantation, [4][5][6][7][8][9][10][11] whether less severe kidney disease is associated with cancer remains poorly understood. [12][13][14][15] Previous studies are limited by modest sample sizes, restricted diversity, and their ability to adequately control for confounders.…”

mentioning

confidence: 99%

CKD and the Risk of Incident Cancer

Lowrance

Ordoñez

Udaltsova

et al. 2014

Journal of the American Society of Nephrology

217

183

View full text Add to dashboard Cite

Previous studies report a higher risk of cancer in patients with ESRD, but the impact of less severe CKD on risk of cancer is uncertain. Our objective was to evaluate the association between level of kidney function and subsequent cancer risk. We performed a retrospective cohort study of 1,190,538 adults who were receiving care within a health care delivery system, had a measurement of kidney function obtained between 2000 and 2008, and had no prior cancer. We examined the association between level of eGFR and the risk of incident cancer; the primary outcome was renal cancer, and secondary outcomes were any cancer and specific cancers (urothelial, prostate, breast, lung, and colorectal). During 6,000,420 person-years of follow-up, we identified 76,809 incident cancers in 72,875 subjects. After adjustment for time-updated confounders, lower eGFR (in milliliters per minute per 1.73 m 2 ) was associated with an increased risk of renal cancer (adjusted hazard ratio [HR], 1.39; 95% confidence interval [95% CI], 1.22 to 1.58 for eGFR=45-59; HR, 1.81; 95% CI, 1.51 to 2.17 for eGFR=30-44; HR, 2.28; 95% CI, 1.78 to 2.92 for eGFR,30). We also observed an increased risk of urothelial cancer at eGFR,30 but no significant associations between eGFR and prostate, breast, lung, colorectal, or any cancer overall. In conclusion, reduced eGFR is associated with an independently higher risk of renal and urothelial cancer but not other cancer types.

show abstract

“…1,2 In their study, Cengiz et al reported that 188 (6.7%) organ tumors of varying pathologies were found in 2817 patients with chronic renal failure 3 . Although it is known to be a common pathology in the general population 4 , the prevalence of renal insufficiency (RI) among patients with cancer has only been recently assessed in the "Renal Insufficiency and Anticancer Medications" (IRMA) study 5 , where we found a high prevalence of renal insufficiency among 4684 solid tumor patients from 15 French cancer centers.…”

Section: Introductionmentioning

confidence: 98%

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

Launay-Vacher

Gligorov

Tourneau

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

1 ST PROPOSITIONThe Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study which demonstrated the high prevalence of abnormal renal function in a population of 4684 solid tumour patients. Among them, 50 to 60% had decreased renal function defined as CrCl below 90, and 80% were treated with anticancer drugs that either necessitated dosage adjustment in case of RI or were potentially nephrotoxic drugs. Since patients and drugs used differ depending on the type of tumour, the IRMA Study Group started analyses in different subgroups of patients. In the 1898 IRMA patients with breast cancer, the prevalence of RI was still very high in spite of a normal serum creatinine in almost all cases. Some anticancer drugs, as in particular some bisphosphonates, capecitabine and platinum salts, may be nephrotoxic and/or need dosage adjustment. However other important drugs in breast cancer do not require dose reduction, and do not present with potential nephrotoxicity (anthracyclines, taxanes, trastuzumab). Both issues seem to be slightly but significantly more important in patients with bone metastases as compared to patients with a non-metastatic disease.Linking powered by eXtyles ABSTRACT: 2 ND PROPOSITION BACKGROUND. The Renal Insufficiency and Anticancer Medications (IRMA) study was a French national observational study. The results from this study of nearly 5000 patients demonstrated the high prevalence of renal impairment in a population of patients with solid tumors with 50 to 60% presenting with a decreased renal function defined as CrCl below 90, and 80% being treated with anticancer drugs that either necessitated dosage adjustment in case of RI or were potentially nephrotoxic drugs. Here are presented the results on patients with breast cancer.METHODS. Every cancer patient who presented at oncology departments that participated in the study over at least 1 of 2 predefined periods during 2004 was included in the IRMA study. Data on patients with breast cancer were analyzed. Renal function was calculated using Cockcroft-Gault and abbreviated Modification of Diet in Renal Disease (aMDRD) formulae to estimate the prevalence of renal insufficiency (RI) according to the KDOQI-KDIGO definition of kidney disease. Anticancer drugs were studied with regard to their potential renal toxicity and need for dosage adjustment.RESULTS. Of the 1898 IRMA breast cancer patients, 1.6% had a SCr level >110 lmol/L. However, when they were assessed using Cockcroft-Gault and aMDRD formulae, 51.8% and 50.8% had abnormal renal function, respectively. Of the 3465 anticancer drug prescriptions, 53.2% required dose adjustments for RI or were drugs with no available data on their administration in patients with RI. Of the patients treated, 90.4% received at least 1 such drug, and 76.9% received potentially nephrotoxic drugs. CONCLUSIONS. In the 1898 IRMA patients with breast cancer, the prevalence of RI was still very high in spite of a normal serum creatinine in almost all cases. Some antica...

show abstract

Increased Incidence of Malignancy During Chronic Renal Failure

Cited by 325 publications

References 13 publications

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

CKD and the Risk of Incident Cancer

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

Contact Info

Product

Resources

About